Catalent and Johnson & Johnson Sign Coronavirus Vaccine Manufacturing Deal

Shares of drug manufacturer Catalent (NYSE:CTLT) were up by 10% at 2 p.m. Wednesday after the company announced it had signed an agreement with the Janssen Pharmaceuticals subsidiary of Johnson & Johnson (NYSE:JNJ) to manufacture a COVID-19 vaccine. The agreement includes joint investment in expanding the capacity of Catalent's Bloomington, Indiana manufacturing facility. The financial terms of the deal were not disclosed.